By Lisa Kerner
Charlotte, N.C., Sept. 25 - NovaCardia closed a $48 million round of series B financing to support development of its small molecule adenosine A1 receptor antagonist and other cardiovascular compounds in its pipeline.
Skyline Ventures led the round, joined by InterWest Partners and previous investors Domain Associates, Forward Ventures, Montreux Equity Partners and Versant Ventures.
David G. Lowe, partner, Skyline Ventures and Nina Kjellson, partner, InterWest Partners were named to NovaCardia's board of directors.
NovaCardia is a San Diego pharmaceutical company.
| Issuer: | NovaCardia
|
| Issue: | Series B financing
|
| Amount: | $48 million
|
| Investors: | Skyline Ventures (lead), InterWest Partners, Domain Associates, Forward Ventures, Montreux Equity Partners, Versant Ventures
|
| Announcement date: | Sept. 25
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
